Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. She received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. She received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Su Lin, MS
VP of Operation Development
Su Lin gained her Master of Science in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years’ experience in the pharmaceutical industry, specifically in regulatory affairs and labeling, and has worked in global pharma such as Intercept and Regeneron Pharmaceuticals.
Su Lin, MS
VP of Operation Development
Su Lin gained her Master of Science in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years’ experience in the pharmaceutical industry, specifically in regulatory affairs and labeling, and has worked in global pharma such as Intercept and Regeneron Pharmaceuticals.
Erin Chang, MS
VP of Portfolio Development
Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Erin Chang, MS
VP of Portfolio Development
Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Mei-Hui Kuo
COO
Mei-Hui Kuo has over 30 years’ experience in the biotechnology pharmaceutical industry. Her most recent role was COO at Senhwa Biosciences, with previous senior positions including VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.
Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Mei-Hui Kuo
COO
Mei-Hui Kuo has over 30 years’ experience in the biotechnology pharmaceutical industry. Her most recent role was COO at Senhwa Biosciences, with previous senior positions including VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.
Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Wen Chyi Shyu, PhD
CEO
With more than two decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and commercial expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in R&D ranges from pre-clinical and clinical drug metabolism to pharmacokinetic drug discovery, drug development, and life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.
Wen Chyi brings to BRIM extensive industry experience and a passion for driving drug discovery and development innovation. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee of the New England Drug Metabolism Discussion Working Group (NEDMDG) to identify and improve the drug discovery process and to shorten study turnaround time. Wen Chyi has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.
She has a passion for training, motivating, and developing research scientists to become successful pharmaceutical executives and has built numerous international and multi-disciplinary teams.
Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Wen Chyi Shyu, PhD
CEO
With more than two decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and commercial expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in R&D ranges from pre-clinical and clinical drug metabolism to pharmacokinetic drug discovery, drug development, and life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.
Wen Chyi brings to BRIM extensive industry experience and a passion for driving drug discovery and development innovation. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee of the New England Drug Metabolism Discussion Working Group (NEDMDG) to identify and improve the drug discovery process and to shorten study turnaround time. Wen Chyi has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.
She has a passion for training, motivating, and developing research scientists to become successful pharmaceutical executives and has built numerous international and multi-disciplinary teams.
Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Haishan Jang, PhD
Vice Chairman, CGS (Chief Global Strategist) of BRIM
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.
Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.
Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Haishan Jang, PhD
Vice Chairman, CGS (Chief Global Strategist) of BRIM
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.
Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.
Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Frank W. Lee
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy.
In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs.
Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Frank W. Lee
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy.
In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs.
Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
